Skip redundant pieces
The Center for Reproductive Sciences

Faculty

insert text description of image
insert text description of image
Benyi Li, MD, PhD
Assistant Professor Urology; Pathology & Laboratory Medicine; Molecular & Integrative Physiology

Research Description

The ultimate goal of the laboratory is to uncover the mechanisms responsible for cancer development and progression at a molecular level, and subsequently to develop a novel therapeutic approach for treatment. The current research directions are (1) determination of the molecular mechanisms involved in androgen-independent progression of human prostate cancer (2) Identification of the exact role of individual MMP in cancer metastasis; and (3) Development of novel therapeutic approaches at a molecular level for prostate cancer therapy. The projects are funded currently by grants from the Department of Defense Prostate Cancer Research Program (PC020015, PC031120), KUMC Lied Foundation, and HOPE Foundation of Southwestern Oncology Group.

Representative Publications

Li B, Thrasher JB. Androgen receptor and cellular survival in prostate cancer. Recent Res Dev Cancer 2005; 7:65-89.

Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005; 4(9):1311-9.

Liao X, Tang S, Griebling T, Thrasher JB, Li B. siRNA-mediated androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Therapeutics 2005; 4(4):505-15.

Liao X, Thrasher JB, Holzbeierlien J, Scott S, Li B. GSK-3b activity is required for androgen-stimulated gene expression. Endocrinology 2004; 145:2941-2949.

Liao X, Zhang L, Du J, Thrasher JB, Li B. GSK-3b suppression eliminates TRAIL resistance in prostate cancer. Mol Cancer Therapeutics 2003; 2:1215-1222.

top of page